Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News


VCPro Database

Topokine Therapeutics Secures New Round of Capital to Advance Clinical Development of Facial Aesthetics Products

BOSTON, Mass., April 2, 2014-- Topokine Therapeutics, a clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body, announced that it has received a new round of venture financing from Schooner Capital, a Boston-based investment firm. Specific terms were not disclosed.

"We continue to be impressed by Topokine's scientific data and clinical advances," said Ted Henderson, a Managing Director at Schooner Capital. "We see a substantial untapped market for topical contouring therapies and believe that Topokine's products, if approved, will be game-changing for facial aesthetics."

"We are pleased to receive additional funding from Schooner Capital," said Murat Kalayoglu, MD, PhD, Topokine President and CEO. "This new round will help advance our growing clinical pipeline and expand our worldwide intellectual property position."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body. The company's lead program, XAF5 Gel, is a topical adipomodulatory product in Phase 2 clinical development for local reduction of excess submental fat ("double chin") and other indications. Topokine's pipeline also includes XOPH5 Ointment to treat steatoblepharon ("eye bags") and TAT4, a topical "filler" therapy to increase local tissue volume.

About Schooner Capital

Founded in 1971, Schooner Capital is a Boston-based private investment firm. The firm approaches all investments with a long-term perspective and invests in private companies across stage and sector, with a focus on quality of management, unit economics, and long-term growth prospects.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are based on current beliefs and expectations, but actual results may differ.

Contact:
Media Contact:
Matt Burke
Topokine Therapeutics, Inc.
1.617.203.2034
matt.burke@topokine.com


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer